CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients
CAR-T therapy shows promising activity in relapsed/refractory Burkitt lymphoma, but its effectiveness is limited by short response duration. High-risk features may predict poor outcomes, and a higher number of long-term survivors were observed in patients who received transplant sequential consolidation. However, due to the small sample size, larger studies are needed to validate these findings.
Authors
- Fan Yang (ORCID: https://orcid.org/0000-0001-9697-7016)
- Xiaoyan Ke (ORCID: https://orcid.org/0000-0002-2195-5397)
- Yuelu Guo
- Kai Hu (ORCID: https://orcid.org/0000-0002-2777-9080)
- Lixia Ma (ORCID: https://orcid.org/0009-0006-3403-3806)
- Miaomiao Cao (ORCID: https://orcid.org/0000-0002-4863-4454)
- Zhonghua Fu
- Chen Chen (ORCID: https://orcid.org/0000-0003-2104-534X)
- Rui Liu (ORCID: https://orcid.org/0000-0003-2661-7183)
- Biping Deng (ORCID: https://orcid.org/0000-0002-3244-9174)
- Qinlong Zheng (ORCID: https://orcid.org/0000-0002-8433-3691)
- Danyang Li (ORCID: https://orcid.org/0000-0002-4795-5766)
Institutions
- Beijing Tongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3389/fonc.2025.1566938
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27